COCH (Envoy Medical) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COCH Envoy Medical Inc COCH
6 GF Score
Price $0.76
GF Value $0.66
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Envoy Medical Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

COCH
6GF Score
Envoy Medical Inc COCH
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Envoy Medical (COCH) Overvalued in 2026?

Based on GuruFocus' analysis, Envoy Medical stock appears to be overvalued. The current stock price of $0.76 is trading 14.8% above its estimated GF Value™ of $0.66. GuruFocus considers Envoy Medical to be Modestly Overvalued.

Key valuation signals for COCH:

  • Interest Received:
  • GF Value™: $0.66 vs. price of $0.76 (14.8% above fair value)
  • GF Score™: 6/100 with 8 warning signs

No single metric tells the full story. See the COCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Envoy Medical Business Description

Address 4875 White Bear Parkway, White Bear Lake, MN, USA, 55110
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
6GF Score

Get the complete analysis for COCH

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price
$0.66
GF Value